Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Not yet recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Breast Neoplasms 88Carcinoma, Non-Small-Cell Lung 86Multiple Myeloma 73Prostatic Neoplasms 63Neoplasms 55Colorectal Neoplasms 46Lymphoma 42Squamous Cell Carcinoma of Head and Neck 41Leukemia, Myeloid, Acute 41Lung Neoplasms 39Pancreatic Neoplasms 32Neoplasm Metastasis 32Carcinoma, Hepatocellular 31Ovarian Neoplasms 30Lymphoma, Large B-Cell, Diffuse 29Carcinoma, Renal Cell 29Urinary Bladder Neoplasms 28Lymphoma, Non-Hodgkin 27Melanoma 26Head and Neck Neoplasms 26Hematologic Neoplasms 25Triple Negative Breast Neoplasms 24Sarcoma 23Precursor Cell Lymphoblastic Leukemia-Lymphoma 23Hodgkin Disease 23Leukemia, Lymphocytic, Chronic, B-Cell 22Glioma 22Stomach Neoplasms 20Myelodysplastic Syndromes 20Lymphoma, Mantle-Cell 19

Interventions

(2S,3R,4R,5S,6R)-2-(4-chloro-3-(4-ethoxybenzyl)phenyl)-6-(methylthio)tetrahydro-2H-pyran-3,4,5-triol 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Ventricular Dysfunction, Left × 30 days × Clear all
NCT07572175 2026-05-07

SPARTACUS

Icahn School of Medicine at Mount Sinai

Phase 2 Not yet recruiting
60 enrolled
Lymphoid

Lymphoma, Ventricular Dysfunction, Left, Cardiotoxicity

Data powered by HemOnc (CC BY 4.0) Colophon âš¡